ABVX Trading Analysis - 10/23/2026 02:31 PM — TRU-SENTIMENT

News Headlines & Context:

Abivax (ABVX) has been in the spotlight following its late-stage clinical development updates for obefazimod in ulcerative colitis, with recent pipeline commentary suggesting continued regulatory engagement with the FDA.

The company remains pre-revenue with a negative EPS, and biotech sector volatility has been elevated around clinical readouts and funding concerns.

No confirmed near-term earnings date is reflected in the embedded data, but historical volatility of 53.85% implies binary-type risk typical of development-stage names.

Context: Options sentiment is bullish on directional conviction, yet the stock is below major moving averages, suggesting traders may be positioning for a catalyst not yet reflected in price or fundamentals.

Fundamental Analysis:

Based strictly on the provided fundamentals data:

• Trailing EPS is -5.85; company is unprofitable with no positive earnings trend available.
• Trailing PE, forward PE, PEG ratio, profit margins, revenue growth, ROE, and debt-to-equity are all null or unavailable.
• Market cap is $7,832,662,000.00 with 87,272,000.00 shares outstanding.
• Dividend yield is 0.00%; no dividend is paid.
• Institutional ownership is low at 12.90%.
• 52-week range: $69.81 low to $148.83 high; current price near lower-middle of range.
• Average volume is 1,316,000.00; historical volatility is 53.85%.
• Analyst consensus, target mean price, and recommendation key are null.

Fundamentals show a pre-revenue biotech with heavy losses and thin institutional support, which diverges from the bullish options sentiment and aligns with the bearish technical structure below major SMAs.

Current Market Position:

Current price from indicators is $89.75 (2026-10-22 close). Daily history shows a decline from $118.64 on 2026-09-11 to $89.75 on 2026-10-22, with a 30-day range high of $119.02 and low of $84.11.

Minute bars for 2026-10-21 open at $93.86 and close near $94.44 early, then fall to $89.65 by 2026-10-22 15:35 before a minor bounce to $90.23 at 15:55. Intraday momentum is weak but stabilizing into the close.

Technical Analysis:

Price is below SMA 5 ($90.18), SMA 20 ($91.03), and well below SMA 50 ($103.93), confirming bearish alignment. RSI at 45.08 shows neutral-to-soft momentum. MACD is negative with histogram -0.81, indicating continuing downside pressure. Bollinger Bands: middle $91.03, upper $98.85, lower $83.21; price sits just below the middle band. The 30-day range is $84.11–$119.02; current price is near the lower quadrant of that range.

True Sentiment Analysis (Delta 40-60 Options):

Options flow via True Sentiment shows Bullish conviction.

Call Dollar Volume: $302,530.00 (84.6%) Put Dollar Volume: $54,925.00 (15.4%) Total: $357,455.00

Call contracts: 344 vs put contracts: 90. Pure directional positioning is heavily call-biased, suggesting near-term expectations of a bounce or catalyst. This diverges from the bearish technicals (price below SMAs, negative MACD), a split signal noted in the option spread recommendation data.

Key Price Levels (Observational Only):